351 related articles for article (PubMed ID: 15355924)
21. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
23. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types.
Fujita T; Teramoto K; Ozaki Y; Hanaoka J; Tezuka N; Itoh Y; Asai T; Fujino S; Kontani K; Ogasawara K
Cancer Res; 2009 Jun; 69(12):5142-50. PubMed ID: 19491278
[TBL] [Abstract][Full Text] [Related]
25. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
26. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
[TBL] [Abstract][Full Text] [Related]
27. Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma.
Cordier Kellerman L; Valeyrie L; Fernandez N; Opolon P; Sabourin JC; Maubec E; Le Roy P; Kane A; Legrand A; Abina MA; Descamps V; Haddada H
Cancer Gene Ther; 2003 Jun; 10(6):481-90. PubMed ID: 12768194
[TBL] [Abstract][Full Text] [Related]
28. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes.
Berg DJ; Lynch RG
J Immunol; 1991 Apr; 146(8):2865-72. PubMed ID: 1826699
[TBL] [Abstract][Full Text] [Related]
29. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
30. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.
Tada T; Ohzeki S; Utsumi K; Takiuchi H; Muramatsu M; Li XF; Shimizu J; Fujiwara H; Hamaoka T
J Immunol; 1991 Feb; 146(3):1077-82. PubMed ID: 1671050
[TBL] [Abstract][Full Text] [Related]
32. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse Renca tumors.
Qin W; Tian F; Wang F; Song B; Wang H; Zhang Q; Jovanovic B; Liang L; Guo Y; Smith N; Lee C
Urology; 2008 Oct; 72(4):943-7. PubMed ID: 18723212
[TBL] [Abstract][Full Text] [Related]
33. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
34. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
[TBL] [Abstract][Full Text] [Related]
35. TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection.
Martin DL; Postan M; Lucas P; Gress R; Tarleton RL
Eur J Immunol; 2007 Oct; 37(10):2764-71. PubMed ID: 17823982
[TBL] [Abstract][Full Text] [Related]
36. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Ashley DM; Kong FM; Bigner DD; Hale LP
Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
[TBL] [Abstract][Full Text] [Related]
37. Expression of transforming growth factor beta isoforms and their receptors in malignant fibrous histiocytoma of soft tissues.
Yamamoto T; Akisue T; Marui T; Fujita I; Matsumoto K; Hitora T; Kawamoto T; Nagira K; Nakatani T; Kurosaka M
Clin Cancer Res; 2004 Sep; 10(17):5804-7. PubMed ID: 15355909
[TBL] [Abstract][Full Text] [Related]
38. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM
Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712
[TBL] [Abstract][Full Text] [Related]
39. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
